标题:Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review
作者:You, Zhu; Liu, Shao-Peng; Du, Jing; Wu, Yi-Hua; Zhang, Shi-Zhou
作者机构:[You, Zhu; Liu, Shao-Peng; Du, Jing] Shandong Univ, Sch Stomatol, Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.; [Y 更多
通讯作者:Zhang, SZ;Wu, YH
通讯作者地址:[Zhang, SZ]Shandong Univ, Shandong Prov Hosp, Dept Oral & Maxillofacial Surg, Jinan, Shandong, Peoples R China;[Wu, YH]Shandong Univ, Shandong Prov Ho 更多
来源:JOURNAL OF ORAL PATHOLOGY & MEDICINE
出版年:2019
卷:48
期:3
页码:201-205
DOI:10.1111/jop.12807
关键词:ameloblastoma; BRaf; mitogen-activated protein kinase signaling; pathways; odontogenic tumor; targeted therapy
摘要:Numerous signal transduction pathways are closely associated with the occurrence, development, and prognosis of ameloblastoma (AM). Mitogen-activated protein kinase (MAPK) is a serine/threonine-specific protein kinase that transduces intracellular signals in critical cellular phenomena. A number of recent analyses have reported that the MAPK signaling pathway contributes significantly to AM. High-throughput DNA sequencing methods, such as next-generation sequencing using Illumina have yielded advancements in studies on MAPK signaling pathways and their association with AM; in particular, BRAF V600E is mediated by the activation of the Ras/Raf/MAPK pathway. This review discusses advancements in studies on MAPK signaling pathways and MAPK-targeted inhibitors or antibodies, along with the merits and demerits of MAPK-targeted therapies, finally followed by a discussion regarding more efficient potential MAPK-targeted therapies to treat AM with few side effects, thereby providing novel insights into targeted therapy for AM.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061005769&doi=10.1111%2fjop.12807&partnerID=40&md5=2f1f564bec6650c88d802e95a6c00c27
TOP